Company Analysis
Sign in

ACADIA Pharmaceuticals Inc. (ACAD)

Nasdaq: ACAD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2000
Full chart Alerts Compare
Grade6.7
◀ Past 7.6● Present 7.2▶ Future 5.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

108 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ACADIA Pharmaceuticals Inc.’s names, not what it holds today.

Patents granted
108
108 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 6 in 2023
Applications published
99
4 of them in 2025
Names they are printed under
8
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals18
Organic fine chemistry7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
ACADIA Pharmaceuticals Inc. its own name
US, as the owner printed on each patent
94 granted
37 published
ACADIA Pharmaceuticals Inc. its own name
named as the applicant on its applications, in US
0 granted
38 published
Levo Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
5 granted
4 published
Amorsa Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
CERSCI THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
Amorsa Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
7 granted
0 published
LEVO THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
CerSci Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,167Crystalline forms of trofinetidePharmaceuticalsACADIA Pharmaceuticals Inc.
Nov 11, 202512,466,783Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methodsPharmaceuticalsACADIA Pharmaceuticals Inc.
Nov 12, 202412,139,477Compounds, salts thereof and methods for treatment of diseasesOrganic fine chemistryACADIA Pharmaceuticals Inc.
Apr 16, 202411,957,656Methods of treating Prader-Willi syndromePharmaceuticalsLevo Therapeutics, Inc.
Dec 19, 202311,844,764Agitation process for preparing a carbetocin drug productPharmaceuticalsACADIA Pharmaceuticals Inc.
Dec 12, 202311,840,515Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form cOrganic fine chemistryACADIA Pharmaceuticals Inc.
Nov 28, 202311,827,600Crystalline forms of trofinetidePharmaceuticalsACADIA Pharmaceuticals Inc.
Mar 28, 202311,613,515Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methodsPharmaceuticalsAmorsa Therapeutics, Inc.
Mar 14, 202311,603,348Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methodsPharmaceuticalsAmorsa Therapeutics, Inc.
Jan 17, 202311,554,100Single-layer oral dose of neuro-attenuating ketaminePharmaceuticalsAmorsa Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367158MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88Organic fine chemistryACADIA Pharmaceuticals Inc.
Dec 4, 20252025/0367143MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88Organic fine chemistryACADIA Pharmaceuticals Inc.
Jun 19, 20252025/0197385COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASESOrganic fine chemistryACADIA Pharmaceuticals Inc.
Jan 16, 20252025/0019347CRYSTALLINE FORMS OF TROFINETIDEPharmaceuticalsACADIA Pharmaceuticals Inc. · patent 12,492,167 granted from it
Dec 19, 20242024/0415806METHODS OF TREATING PRADER-WILLI SYNDROMEPharmaceuticalsLEVO THERAPEUTICS, INC.
Jul 18, 20242024/0240179THERAPY FOR TREATMENT OF PRADER-WILLI SYNDROMEBiotechnologyLEVO THERAPEUTICS, INC.
Apr 25, 20242024/0132450MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88Organic fine chemistryACADIA Pharmaceuticals Inc.
Mar 21, 20242024/0091302CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING SAMEPharmaceuticalsACADIA Pharmaceuticals Inc.
Mar 21, 20242024/0091212SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASESPharmaceuticalsACADIA Pharmaceuticals Inc.
Jun 29, 20232023/0201300STABLE INTRANASAL FORMULATIONS OF CARBETOCINPharmaceuticalsLevo Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 4 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ACAD · research, not advice